MRK•benzinga•
Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics
Summary
Summit Therapeutics' ivonescimab shows strong efficacy in trials, with Cantor Fitzgerald predicting a 50% market share in the $100B VEGF x PD-(L)1 space.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 24, 2025 by benzinga